Nektar Therapeutics - NKTR Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $8.40
  • Forecasted Upside: 185.71 %
  • Number of Analysts: 12
  • Breakdown:
  • 3 Sell Ratings
  • 7 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.94
▲ +0.03 (1.03%)

This chart shows the closing price for NKTR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Nektar Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NKTR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NKTR

Analyst Price Target is $8.40
▲ +185.71% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Nektar Therapeutics in the last 3 months. The average price target is $8.40, with a high forecast of $21.00 and a low forecast of $3.00. The average price target represents a 185.71% upside from the last price of $2.94.

This chart shows the closing price for NKTR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 12 contributing investment analysts is to hold stock in Nektar Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 1 sell ratings
6/15/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 2 sell ratings
9/13/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 1 sell ratings
12/12/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 1 sell ratings
3/12/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 7 hold ratings
  • 2 sell ratings
6/10/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 7 hold ratings
  • 3 sell ratings
9/8/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 7 hold ratings
  • 3 sell ratings
11/7/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 3 sell ratings
12/7/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 3 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/8/2022JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightLow
4/20/2022OppenheimerDowngradeOutperform ➝ Market PerformMedium
4/18/2022The Goldman Sachs GroupDowngradeNeutral ➝ Sell$3.00High
4/18/2022SVB LeerinkLower TargetMarket Perform$7.00 ➝ $6.00High
4/18/2022MizuhoLower TargetNeutral$8.00 ➝ $6.00Low
3/16/2022Canaccord Genuity GroupLower TargetBuy$25.00 ➝ $6.00High
3/16/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$25.00 ➝ $6.00Medium
3/15/2022SVB LeerinkLower TargetMarket Perform$18.00 ➝ $7.00High
3/15/2022MizuhoDowngradeBuy ➝ Neutral$35.00 ➝ $8.00High
3/14/2022CowenDowngradeOutperform ➝ Market Perform$35.00 ➝ $8.00High
3/14/2022OppenheimerDowngradeOutperform ➝ Market PerformHigh
3/14/2022Stifel NicolausDowngradeBuy ➝ Hold$24.00 ➝ $5.00High
3/14/2022BTIG ResearchDowngradeBuy ➝ NeutralHigh
3/14/2022William BlairDowngradeOutperform ➝ Market PerformHigh
3/14/2022Bank of AmericaDowngradeNeutral ➝ Underperform$18.00 ➝ $6.00High
3/9/2022OppenheimerUpgradeMarket Perform ➝ Outperform$21.00Medium
3/1/2022JPMorgan Chase & Co.Lower Target$24.00 ➝ $17.00High
11/8/2021BTIG ResearchLower TargetPositive ➝ Buy$80.00 ➝ $54.00High
11/8/2021SVB LeerinkLower TargetMarket Perform$19.00 ➝ $18.00High
11/8/2021BenchmarkUpgradeHold ➝ Buy$20.00High
11/5/2021OppenheimerLower TargetMarket Perform$25.00 ➝ $21.00High
9/10/2021Bank of AmericaInitiated CoverageNeutral$18.00Low
8/6/2021SVB LeerinkLower TargetMarket Perform$20.00 ➝ $19.00Low
6/28/2021Stifel NicolausUpgradeHold ➝ Buy$22.00 ➝ $24.00Medium
5/10/2021SVB LeerinkLower TargetMarket Perform$21.00 ➝ $20.00Low
5/7/2021MizuhoReiterated RatingBuyHigh
4/6/2021SVB LeerinkBoost TargetMarket Perform$20.00 ➝ $21.00Low
3/1/2021BenchmarkReiterated RatingBuy ➝ Hold$26.00Low
2/22/2021BenchmarkDowngradeBuy ➝ Hold$26.00High
1/5/2021Stifel NicolausInitiated CoverageHold$18.00N/A
11/12/2020SVB LeerinkBoost TargetMarket Perform$17.00 ➝ $20.00Low
9/14/2020JPMorgan Chase & Co.Initiated CoverageNeutral$26.00High
8/14/2020SVB LeerinkLower TargetMarket Perform$18.00 ➝ $17.00Medium
8/7/2020OppenheimerReiterated RatingHold$25.00High
6/10/2020CfraDowngradeHold ➝ SellLow
5/26/2020MizuhoInitiated CoverageBuy$35.00Low
5/18/2020OppenheimerBoost TargetMarket Perform$24.00 ➝ $25.00Medium
5/12/2020HC WainwrightLower TargetNeutral$32.00 ➝ $26.00High
5/8/2020SVB LeerinkBoost TargetMarket Perform$17.00 ➝ $18.00High
4/22/2020BenchmarkInitiated CoverageBuy$26.00Medium
4/2/2020MizuhoReiterated RatingBuy$35.00High
3/30/2020The Goldman Sachs GroupUpgradeSell ➝ Neutral$18.00 ➝ $20.00Low
3/9/2020JPMorgan Chase & Co.Lower TargetNeutral$28.00 ➝ $27.00High
3/4/2020BarclaysInitiated CoverageOverweight$30.00High
2/28/2020Piper SandlerReiterated RatingBuy$35.00High
2/28/2020BTIG ResearchLower TargetBuy$101.00 ➝ $80.00High
2/28/2020William BlairReiterated RatingOutperformHigh
2/28/2020CowenReiterated RatingBuy$27.00Low
2/12/2020CowenReiterated RatingBuy$30.00Medium
2/3/2020MizuhoReiterated RatingNeutral ➝ Buy$21.00 ➝ $35.00High
1/10/2020MizuhoInitiated CoverageHold$21.00High
1/10/2020HC WainwrightReiterated RatingHold$32.00High
11/11/2019HC WainwrightBoost TargetNeutral$24.00 ➝ $32.00High
11/7/2019Piper Jaffray CompaniesLower TargetOverweight$50.00 ➝ $35.00High
11/7/2019CowenReiterated RatingBuyHigh
11/7/2019MizuhoReiterated RatingHold$21.00High
10/24/2019OppenheimerInitiated CoverageMarket Perform$18.00Medium
10/8/2019The Goldman Sachs GroupDowngradeBuy ➝ Sell$54.00 ➝ $16.00High
9/30/2019HC WainwrightSet TargetHold$24.00High
9/26/2019CowenSet TargetBuy$43.00Medium
9/26/2019William BlairReiterated RatingBuyMedium
9/26/2019Piper Jaffray CompaniesSet TargetBuy$50.00Medium
8/13/2019HC WainwrightReiterated RatingHoldMedium
8/11/2019Evercore ISIReiterated RatingHold$37.00High
8/9/2019William BlairReiterated RatingBuyLow
8/9/2019CfraSet TargetHold$35.00Low
8/9/2019BMO Capital MarketsLower TargetOutperform$75.00 ➝ $41.00High
8/9/2019MizuhoDowngradeBuy ➝ Neutral$79.00 ➝ $21.00High
8/9/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$62.00 ➝ $33.00High
8/9/2019Jefferies Financial GroupDowngradeBuy ➝ Hold$59.00 ➝ $23.00High
8/9/2019Piper Jaffray CompaniesBoost TargetOverweight$50.00 ➝ $100.00High
7/26/2019MizuhoLower TargetBuy$81.00 ➝ $79.00High
6/14/2019William BlairReiterated RatingBuyMedium
6/13/2019CowenSet TargetBuy$82.00Medium
6/4/2019William BlairReiterated RatingBuyMedium
6/2/2019CowenSet TargetBuy$82.00High
5/24/2019MizuhoReiterated RatingBuy$81.00Low
3/15/2019SVB LeerinkInitiated CoverageMkt Perform$38.00Medium
3/4/2019HC WainwrightReiterated RatingHold$47.00Low
3/1/2019Piper Jaffray CompaniesSet TargetBuy$100.00Low
3/1/2019MizuhoReiterated RatingBuy$81.00High
2/22/2019BMO Capital MarketsInitiated CoverageOutperform$75.00Medium
2/19/2019MizuhoReiterated RatingBuyLow
2/19/2019HC WainwrightReiterated RatingHold$47.00Low
1/23/2019MizuhoReiterated RatingBuy$81.00 ➝ $81.00Low
12/13/2018The Goldman Sachs GroupInitiated CoverageSell ➝ Buy$81.00 ➝ $62.00High
11/12/2018HC WainwrightSet TargetHold$47.00High
11/8/2018CowenReiterated RatingBuy$86.00High
11/8/2018Jefferies Financial GroupLower TargetBuy ➝ Buy$103.00 ➝ $73.00High
11/5/2018HC WainwrightReiterated RatingHold$47.00Medium
10/22/2018HC WainwrightSet TargetHold$54.00High
8/10/2018HC WainwrightSet TargetHold$54.00Medium
8/9/2018William BlairReiterated RatingOutperformHigh
8/9/2018CowenReiterated RatingBuy$86.00High
8/9/2018MizuhoReiterated RatingBuy$103.00High
8/8/2018Piper Jaffray CompaniesSet TargetBuy$125.00High
7/31/2018HC WainwrightReiterated RatingHold$54.00Low
7/25/2018Piper Jaffray CompaniesSet TargetBuy$125.00High
6/11/2018HC WainwrightDowngradeBuy ➝ Neutral$54.00Low
6/4/2018William BlairReiterated RatingBuyHigh
6/4/2018JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$90.00 ➝ $78.00High
6/4/2018HC WainwrightLower TargetBuy$97.00High
5/20/2018HC WainwrightSet TargetBuy$125.00Low
5/14/2018HC WainwrightSet TargetBuy$125.00Medium
5/11/2018Piper Jaffray CompaniesSet TargetBuy$125.00High
4/30/2018HC WainwrightSet TargetBuy$125.00Low
4/26/2018Piper Jaffray CompaniesSet TargetBuy$125.00Low
4/17/2018HC WainwrightSet TargetBuy$125.00Low
4/17/2018MizuhoReiterated RatingBuy$103.00Low
4/13/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$125.00Medium
4/9/2018HC WainwrightSet TargetBuy$125.00High
4/6/2018MizuhoBoost TargetBuy ➝ Buy$89.00 ➝ $103.00Medium
4/2/2018HC WainwrightReiterated RatingBuy ➝ Buy$125.00High
3/29/2018MizuhoSet TargetBuy$89.00Low
3/2/2018CowenReiterated RatingBuy$101.00Low
3/2/2018Jefferies Financial GroupBoost TargetBuy$103.00High
2/14/2018MizuhoReiterated RatingBuy$89.00Medium
1/22/2018MizuhoBoost TargetBuy ➝ Buy$45.00 ➝ $89.00High
1/16/2018Jefferies Financial GroupBoost TargetBuy$2.12 ➝ $88.00High
(Data available from 12/7/2017 forward)

News Sentiment Rating

0.23 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 10 positive mentions
  • 6 negative mentions
  • 4 very negative mentions
5/11/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
6/10/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/10/2022
  • 2 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
8/9/2022
  • 2 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/8/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/8/2022
  • 1 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
11/7/2022
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
12/7/2022

Current Sentiment

  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Nektar Therapeutics logo
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $2.94
Low: $2.89
High: $3.01

50 Day Range

MA: $3.47
Low: $2.80
High: $4.28

52 Week Range

Now: $2.94
Low: $2.73
High: $15.94

Volume

53,355 shs

Average Volume

2,194,186 shs

Market Capitalization

$552.57 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1

Frequently Asked Questions

What sell-side analysts currently cover shares of Nektar Therapeutics?

The following sell-side analysts have issued stock ratings on Nektar Therapeutics in the last year: Bank of America Co., BTIG Research, Canaccord Genuity Group Inc., Cowen Inc, JPMorgan Chase & Co., Mizuho, Oppenheimer Holdings Inc., Stifel Nicolaus, StockNews.com, SVB Leerink LLC, The Goldman Sachs Group, Inc., and William Blair.
View the latest analyst ratings for NKTR.

What is the current price target for Nektar Therapeutics?

10 Wall Street analysts have set twelve-month price targets for Nektar Therapeutics in the last year. Their average twelve-month price target is $8.40, suggesting a possible upside of 185.7%. Oppenheimer Holdings Inc. has the highest price target set, predicting NKTR will reach $21.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $3.00 for Nektar Therapeutics in the next year.
View the latest price targets for NKTR.

What is the current consensus analyst rating for Nektar Therapeutics?

Nektar Therapeutics currently has 3 sell ratings, 7 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in NKTR, but not buy more shares or sell existing shares.
View the latest ratings for NKTR.

What other companies compete with Nektar Therapeutics?

How do I contact Nektar Therapeutics' investor relations team?

Nektar Therapeutics' physical mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The biopharmaceutical company's listed phone number is (415) 482-5300 and its investor relations email address is [email protected] The official website for Nektar Therapeutics is www.nektar.com. Learn More about contacing Nektar Therapeutics investor relations.